IgA nephropathy trials in Brazil
5 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.
- Phase 2Taking peopleA Study to Assess the Effects of Zigakibart on IgA Nephropathy.
- Where
- Botucatu, Natal, Recife, Serra
- Age
- 18 years and over
- People
- 32 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT07146906 · EU 2024-519699-24-00 - Phase 3Taking peopleA Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)
- Where
- Belo Horizonte, Caxias do Sul, Juiz de Fora, Porto Alegre, São Paulo
- Age
- 18 years and over
- People
- 454 worldwide
- Run by
- Biogen
See details and how to joinNCT06935357 · EU 2024-519345-30-00 - Phase 3Taking peopleA Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy
- Where
- Belo Horizonte, Curitiba, Porto Alegre, São José do Rio Preto, São Paulo
- Age
- 18 years to 100 years
- People
- 540 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT04557462 · EU 2023-508690-92-00 - Phase 2Taking peopleA Phase 2 Study to Evaluate the Safety, PD, PK, and Clinical Activity of ADX-097 in Participants With IgAN, LN or C3G
- Where
- São Paulo
- Age
- 16 years and over
- People
- 30 worldwide
- Run by
- Akebia Therapeutics
See details and how to joinNCT06419205 - Phase 2/3Enrolling by invitationTrial of Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy (IgAN)
- Where
- Joinville, Porto Alegre, Recife, Rio de Janeiro, São José do Rio Preto, São Paulo
- Age
- 18 years and over
- People
- 600 worldwide
- Run by
- Otsuka Pharmaceutical Development & Commercialization, Inc.
See details and how to joinNCT05248659